Quantitative modeling predicts competitive advantages of a next generation anti‐NKG2A monoclonal antibody over monalizumab for the treatment of cancer

• Autori principali: Phillip Spinosa (Autore), Monika Musial‐Siwek (Autore), Marc Presler (Autore), Alison Betts (Autore), Emily Rosentrater (Autore), Janice Villali (Autore), Lucia Wille (Autore), Yang Zhao (Autore), Tom McCaughtry (Autore), Kalyanasundaram Subramanian (Autore), Hanlan Liu (Autore)
• Natura: Libro
• Pubblicazione: Wiley, 2021-03-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract A semimechanistic pharmacokinetic (PK)/receptor occupancy (RO) model was constructed to differentiate a next generation anti‐NKG2A monoclonal antibody (KSQ mAb) from monalizumab, an immune checkpoint inhibitor in multiple clinical trials for the treatment of solid tumors. A three‐compartmen...